May 8th 2025
Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.
PBM Challenges and the Evolving Role of Oncology Pharmacists in Community Practices
April 30, 2025 | 11:15 AM ET
View More
Strategies for Integrating Biologic Therapy Into the Management of Eosinophilic Esophagitis
1.5 Credits / Immunology, Gastroenterology
View More
Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care...
May 20, 2025 | 1:00 PM and 8:00 PM ET
View More
Navigating Next-Generation Therapies for the Management of Acid-Related Disorders
1.5 Credits / Gastroenterology
View More
Biologic Therapy for the Management of Eosinophilic Esophagitis in Children: The Evolving Treatment Paradigm
1.5 Credits / Gastroenterology, Immunology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Foundations in the Management of Eosinophilic Esophagitis: Pathophysiology, Clinical, Economic, and Quality of...
1.0 Credit / Gastroenterology, Immunology
View More
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
1.0 Credit / Gastroenterology, Immunology, Rare Diseases
View More
The Evolving Treatment Paradigm for the Management of Eosinophilic Esophagitis and the Future of Oral Therapie...
1.0 Credit / Gastroenterology, Immunology
View More
The Role of the Community Pharmacist in the Management of Eosinophilic Esophagitis
1.0 Credit / Gastroenterology, Immunology
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Optimizing Treatment Strategies: A Comprehensive Approach to Primary Biliary Cholangitis and Pruritus
1.5 Credits / Hematologic Cancer, Hematology, Oncology
View More